SCHEMBL6489327

SCHEMBL6489327

CC(C)Oc1ccc(-c2ccc(Cl)cc2)c(C(=O)O)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
MAP4K4 O95819 3/20 0.48
PRKAB2 O43741 2/20 0.47
PRKAG1 P54619 2/20 0.47
PRKAA2 P54646 2/20 0.47
PRKAA1 Q13131 2/20 0.47
PRKAG3 Q9UGI9 2/20 0.47
PRKAG2 Q9UGJ0 2/20 0.47
PRKAB1 Q9Y478 2/20 0.47
MCL1 Q07820 2/20 0.47
KMT2A Q03164 2/20 0.46
PTPN11 Q06124 2/20 0.46
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
HSD17B10 Q99714 1/20 0.45
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
ANO1 Q5XXA6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL592412 0.88 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2MAP4K4PRKAB2PRKAG1
SCHEMBL6492074 0.87 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2PRKAB2PRKAG1PRKAA2
SCHEMBL6499746 0.85 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2MCL1KMT2APTPN11
SCHEMBL3816798 0.85 SMN1; SMN2 (0.82) SMN1; SMN2PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL6489788 0.82 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2MCL1KMT2APTPN11
SCHEMBL6492999 0.81 SMN1; SMN2 (0.57) ALDH1A1SMN1; SMN2PRKAB2PRKAG1PRKAA2
SCHEMBL6498907 0.81 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL10058714 0.79 PTPN11 (0.65) SMN1; SMN2PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL8984342 0.78 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2PRKAB2PRKAG1PRKAA2
SCHEMBL15935967 0.78 ALDH1A1 (0.71) ALDH1A1PRKAB2PRKAG1PRKAA2PRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 ALDH1A1 1603/4885SMN1; SMN2 1921/4885MAP4K4 4205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.